Scynexis Inc SCYX

NAS: SCYX | ISIN: US8112921015   17/09/2025
0,990 USD (-6,60%)
(-6,60%)   17/09/2025

8 januari 2024 · Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC Announces that SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! · Persbericht

4 januari 2024 · SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit · Persbericht

28 december 2023 · SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options · Persbericht

21 december 2023 · SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options · Persbericht

15 december 2023 · SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit · Persbericht

5 december 2023 · SCYNEXIS SHAREHOLDER ACTION REMINDER: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $25,000 In Scynexis To Contact Him Directly To Discuss Their Options · Persbericht

1 december 2023 · SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit · Persbericht

12 november 2023 · ROSEN, TRIAL ATTORNEYS, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX · Persbericht

6 oktober 2023 · The Law Offices of Frank R. Cruz Announces Investigation of SCYNEXIS, Inc. (SCYX) on Behalf of Investors · Persbericht

30 september 2021 · Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2021 · Persbericht

5 augustus 2021 · Acurx Pharmaceuticals Joins the Antimicrobials Working Group · Persbericht

8 juni 2021 · Crestone Joins Antimicrobials Working Group · Persbericht

2 maart 2021 · SCYNEXIS Announces Positive Results from Interim Analyses of Ongoing Phase 3 Studies (FURI and CARES), Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting · Persbericht

25 februari 2021 · SCYNEXIS to Participate in Maxim Group’s Late Stage Innovations in Women’s Health Virtual Event · Persbericht

23 februari 2021 · SCYNEXIS and Amplity Health Announce Agreement to Support the Anticipated U.S. Commercialization of BrexafemmeTM (Ibrexafungerp) for Vaginal Yeast Infections · Persbericht

17 februari 2021 · UTILITY Therapeutics Joins Antimicrobials Working Group · Persbericht

17 februari 2021 · SCYNEXIS Announces Licensing Agreement and Strategic Partnership with Hansoh Pharma for Rights to Ibrexafungerp in Greater China · Persbericht

Mijn selecties